COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00435253
Recruitment Status : Completed
First Posted : February 14, 2007
Last Update Posted : October 24, 2011
Information provided by (Responsible Party):
Aeris Therapeutics

Brief Summary:
Evaluate the efficacy and safety of the 10 mL BLVR System in 1 or 2 treatment sessions (8 subsegments, 4 in each lung) in patients with advanced upper lobe predominant emphysema.

Condition or disease Intervention/treatment Phase
Pulmonary Emphysema Biological: BLVR Treatment Phase 2

Detailed Description:
Prospective, open-label, non-controlled, multi-center Phase 2 Study evaluating the efficacy and safety of the 10 mL BLVR System in patients with advanced upper lobe predominant emphysema. Twenty patients will be divided into 2 groups of 10 patients each and treated under conscious sedation at a total of 8 subsegments. Group 1 will be treated in 4 subsegments in 1 lung and have a second treatment of 4 subsegments in the other lung 6 to 12 weeks later. Group 2 will receive treatment at 8 subsegments (4 in each lung) during a single treatment session if possible; if not completed in 1 session the remaining subsegments will be treated 6 to 12 weeks later. Patients will be followed 96 weeks after completion of the final BLVR treatment. All patients will receive standard medical therapy in addition to BLVR treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Study of the Biologic Lung Volume Reduction System (BLVR) in Patients With Advanced Upper Lobe Predominant Emphysema
Study Start Date : February 2007
Actual Primary Completion Date : June 2009
Actual Study Completion Date : June 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Emphysema

Arm Intervention/treatment
Experimental: BLVR Treatment
BLVR Treatment
Biological: BLVR Treatment
BLVR Treatment, 10 mL Hydrogel

Primary Outcome Measures :
  1. Reduction in gas trapping [ Time Frame: 12 weeks post treatment ]
  2. SAEs - Safety of treatment and the procedure [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Improvement in vital capacity [ Time Frame: 12 weeks post treatment ]
  2. Improvement in expiratory flow [ Time Frame: 12 weeks post treatment ]
  3. Improvement in inspiratory flow [ Time Frame: 12 weeks post treatment ]
  4. Improvement in dyspnea symptoms (breathlessness) [ Time Frame: 12 weeks post treatment ]
  5. Improvement in exercise capacity [ Time Frame: 12 weeks post treatment ]
  6. Improvement in respiratory quality of life [ Time Frame: 12 weeks post treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • clinical diagnosis of advanced upper lobe predominant emphysema
  • age >/= 40 years
  • clinically significant dyspnea
  • failure of standard medical therapy to relieve symptoms (inhaled beta agonist and inhaled anticholinergic)
  • pulmonary function tests within protocol-specified ranges (post bronchodilator FEV1 < 45% predicted and experiencing < 30% or 300 mL improvement using bronchodilator; TLC > 110% predicted; RV > 150% predicted)
  • 6 Minute Walk Distance >/= 150 m

Exclusion Criteria:

  • alpha-1 protease inhibitor deficiency
  • homogeneous disease
  • tobacco use within 4 months of initial visit
  • body mass index < 15 kg/m2 or > 35 kg/m2
  • clinically significant asthma, chronic bronchitis or bronchiectasis
  • allergy or sensitivity to procedural components
  • pregnant, lactating or unwilling to use birth control if required
  • prior lung volume reduction surgery, lobectomy, pneumonectomy, lung transplant, endobronchial valve placement, airway stent placement or pleurodesis
  • comorbid condition that could adversely influence outcomes
  • inability to tolerate bronchoscopy under conscious sedation (or anesthesia)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00435253

Layout table for location information
United States, Alabama
University of Alabama Birmingham Lung Health Center
Birmingham, Alabama, United States, 35249
United States, Arizona
Pulmonary Associates
Phoenix, Arizona, United States, 85006
United States, Massachusetts
Caritas St Elizabeth's Med Cen
Boston, Massachusetts, United States, 02135
United States, Pennsylvania
Temple University Lung Center
Philadelphia, Pennsylvania, United States, 01940
United States, South Carolina
Medical University of South Carolina Hospital
Charleston, South Carolina, United States, 29425
Sponsors and Collaborators
Aeris Therapeutics
Layout table for investigator information
Principal Investigator: Victor Pinto-Plata, MD Steward St. Elizabeth's Medical Center of Boston, Inc.
Principal Investigator: Gerard Criner, MD Temple University Lung Center
Principal Investigator: Mark Gotfried, MD Pulmonary Associates
Principal Investigator: Charlie Strange, MD Medical Univ South Carolina Hospital
Principal Investigator: Mark Dransfield, MD Univ of Alabama Birmingham Lung Health Center
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Aeris Therapeutics Identifier: NCT00435253    
Other Study ID Numbers: 01-C06-003
First Posted: February 14, 2007    Key Record Dates
Last Update Posted: October 24, 2011
Last Verified: October 2011
Keywords provided by Aeris Therapeutics:
lung volume reduction
biologic lung volume reduction
bronchoscopic lung volume reduction
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Emphysema
Pathologic Processes
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases